• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    BD Reports First Quarter Fiscal 2025 Financial Results

    2/5/25 4:30:00 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care
    Get the next $BDX alert in real time by email

    Company Delivers Revenue, Margin and Earnings Ahead of its Expectations

    • Revenue of $5.2 billion increased 9.8% as reported, 9.6% currency-neutral and 3.9% organic
    • GAAP and adjusted diluted EPS of $1.04 and $3.43 grew 8.3% and 28.0%, respectively
    • BD completes $750 million share repurchase to date in FY25
    • Company increases FY25 adjusted diluted EPS guidance at the midpoint while absorbing translational currency1

    FRANKLIN LAKES, N.J., Feb. 5, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced results for its fiscal 2025 first quarter which ended December 31, 2024.

    "We delivered strong operational performance in Q1, with revenue growth, margin expansion and earnings per share all ahead of our expectations," said Tom Polen, chairman, CEO and president of BD. "We continue to transform our company through BD 2025, and our intention to separate Biosciences and Diagnostic Solutions builds on the strong foundation and momentum of our strategy. This separation is designed to unlock significant value for both 'New BD' and Biosciences and Diagnostic Solutions as each focuses on maximizing growth, delivering leading innovation and operational excellence in their respective markets. Our talented teams continue to drive solid execution of BD 2025 and meaningful innovation in these businesses and across BD."

    1 BD does not attempt to provide reconciliations of forward-looking adjusted diluted EPS guidance to the comparable GAAP measure. See the discussion below under "Assumptions and Outlook for Full Year Fiscal 2025."

    Recent Business Highlights

    • The company announced the BD board authorized the repurchase of up to 10 million shares of BD common stock in addition to the shares that remain available under the board's previous authorization in 2021.
    • BD Medical:
      • The Medication Delivery Solutions business unit announced:
        • Additional investments in its U.S. manufacturing network to add capacity for critical medical devices, including syringes, needles and IV catheters, to meet the ongoing needs of the nation's health care system.
        • Carilion Clinic is the first health system in Virginia to offer needle-free in-patient blood draws using the BD® PIVO™ Pro Needle-free Blood Collection Device, redefining the standard of care for patients and delivering on the vision of a "One-Stick Patient Experience." 
    • BD Life Sciences:
      • The Specimen Management business unit announced an expansion of innovative fingertip blood testing for use by U.S. health systems and other large provider networks in settings like urgent cares, doctor offices and other ambulatory care settings. This blood testing process integrates BD's MiniDraw™ Capillary Blood Collection System with Babson's BetterWay technologies.
      • The Diagnostic Solutions business unit announced the BD Onclarity™ HPV Assay has officially been added to the American Society for Colposcopy and Cervical Pathology (ASCCP) Enduring Risk-Based Management Guidelines, due to its ability to individually identify more high-risk types of HPV than any other test on the market. The company also announced the assay will be used in a first of its kind Human Papillomavirus (HPV) self-collection study to improve cervical cancer screening in underserved communities. The BD Onclarity™ HPV Assay was approved earlier this year by the U.S. Food and Drug Administration (FDA) for HPV self-collection screening in health care settings.
      • The Biosciences business unit announced a collaboration with Biosero to enable robotic integration with BD flow cytometers to accelerate drug discovery and development.

    First Quarter Fiscal 2025 Operating Results





    Three Months Ended December 31,



    Reported

    Change



    Foreign

    Currency

    Neutral

    Change1



    Organic

    Revenue

    Change1,2

    (Millions of dollars, except per share amounts)



    2024



    2023







    Revenues



    $               5,168



    $               4,706



    9.8 %



    9.6 %



    3.9 %























    Reported Diluted Earnings per Share



    $                 1.04



    $                 0.96



    8.3 %



    7.3 %





    Adjusted Diluted Earnings per Share1



    $                 3.43



    $                 2.68



    28.0 %



    27.6 %





    1Represents a non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in the attached financial tables. 

    2Organic Revenue growth denotes foreign currency neutral revenues further adjusted for the impact to revenues from acquisitions and divestitures during the first 12 months post-acquisition/divestiture.

     

    Geographic Results

    Revenues (Millions of dollars)



    Three Months Ended December 31,



    Reported Change



    Foreign Currency

    Neutral Change1





    2024



    2023





    United States



    $               3,080



    $               2,749



    12.0 %



    12.0 %



















    International



    $               2,089



    $               1,957



    6.7 %



    6.3 %



















    Total Revenues



    $               5,168



    $               4,706



    9.8 %



    9.6 %

    1Represents a non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in the attached financial tables.

     

    Segment Results

    Revenues (Millions of dollars)



    Three Months Ended December 31,



    Reported

    Change



    Foreign Currency

    Neutral Change1



    Organic Revenue

    Change1,2





    2024



    2023







    BD Medical



    $               2,615



    $               2,230



    17.3 %



    17.1 %



    5.0 %























    BD Life Sciences



    $               1,297



    $               1,288



    0.7 %



    0.5 %



    0.5 %























    BD Interventional



    $               1,257



    $               1,188



    5.8 %



    5.5 %



    5.5 %























    Total Revenues



    $               5,168



    $               4,706



    9.8 %



    9.6 %



    3.9 %

    1Represents a non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in the attached financial tables.

    2Organic Revenue growth denotes foreign currency neutral revenues further adjusted for the impact to revenues from acquisitions and divestitures during the first 12 months post-acquisition/divestiture. 

     

    The BD Medical segment includes the Medication Delivery Solutions (MDS), Medication Management Solutions (MMS) and Pharmaceutical Systems (PS) business units, and the Advanced Patient Monitoring (APM) business unit. BD Medical performance reflects the revenue contribution from APM, which was formed upon the closing of the acquisition of Critical Care from Edwards Lifesciences on September 3, 2024. BD Medical organic revenue growth was led by MDS and MMS.

    • MDS performance reflects increased volumes and share gains in Vascular Access Management and strong performance in hypodermic products.
    • MMS performance reflects double-digit growth in Infusion driven by BD Alaris™ that was partially offset by capital seasonality and the prior-year comparisons in Dispensing Solutions and Pharmacy Automation.
    • PS performance reflects timing in Biologics and transitory market dynamics that resulted in lower demand for prefillable syringes.

    The BD Life Sciences segment includes the Specimen Management (SM), Diagnostic Solutions (DS) and Biosciences (BDB) business units. BD Life Sciences revenue growth was driven by performance in SM and DS.

    • SM performance reflects broad volume strength across the BD Vacutainer™ portfolio and customer upgrades to clinically differentiated, higher-value products.
    • DS performance reflects strength in BD Kiestra™ Lab Automation and BD MAX™ IVD that was partially offset by the delayed start to the U.S. respiratory season.
    • BDB performance reflects transitory market dynamics that resulted in lower demand for research solutions in China and the U.S. as expected, partially offset by licensing revenue and double-digit growth in U.S. clinical solutions.

    The BD Interventional segment includes the Surgery, Peripheral Intervention (PI), and Urology & Critical Care (UCC) business units. BD Interventional revenue growth was driven by performance across the segment.

    • Surgery performance reflects double-digit growth in Infection Prevention and Phasix™ hernia resorbable scaffold.
    • PI performance reflects strong growth in the Peripheral Vascular Disease and End Stage Kidney Disease portfolios that was partially offset by the expected impact of volume-based procurement in China, primarily in our Oncology business.
    • UCC performance reflects double-digit growth in the PureWick™ franchise with continued adoption of the Male and Female portfolios.

    Assumptions and Outlook for Full Year Fiscal 2025

    The company provided the following guidance with respect to fiscal 2025.

    The company updated its fiscal 2025 guidance to reflect strong operational performance in its fiscal first quarter and confidence in its full-year outlook. The company increased its Adjusted Diluted EPS guidance to a range of $14.30 to $14.60, which reflects growth of 10% at the midpoint. This reflects an operational increase of $0.175 compared to its previously issued guidance, which is enabling it to absorb the estimated impact of incremental translational foreign currency of $0.15.



    Fiscal 2025 Guidance as of

    February 5, 2025

    Fiscal 2025 Guidance as of

    November 7, 2024

    GAAP Revenues

    ~$21.7 to $21.9 billion

    ~$21.9 to $22.1 billion

    GAAP Revenue Growth

    7.9% to 8.4%

    8.9% to 9.4%

    Adjusted Revenue Growth (FXN)

    8.8% to 9.3%

    8.8% to 9.3%

    Organic Revenue Growth (FXN)

    4.0% to 4.5%

    4.0% to 4.5%

    Adjusted Diluted EPS

    $14.30 to $14.60

    $14.25 to $14.60

    Adjusted Diluted EPS Growth

    ~8.8% to 11.0%

    ~8.5% to 11.0%

     

    BD's outlook for fiscal 2025 reflects numerous assumptions about many factors that could affect its business, based on the information management has reviewed as of this date. Management will discuss its outlook and several of its assumptions on its first fiscal quarter earnings call.

    The company's expected adjusted diluted EPS for fiscal 2025 excludes potential charges or gains that may be recorded during the fiscal year, such as, among other things, the non-cash amortization of intangible assets, acquisition-related charges, spin-related costs, and certain tax matters. BD does not attempt to provide reconciliations of forward-looking adjusted diluted non-GAAP EPS guidance to the comparable GAAP measure because the impact and timing of these potential charges or gains are inherently uncertain and difficult to predict and are unavailable without unreasonable efforts. In addition, the company believes such reconciliations would imply a degree of precision and certainty that could be confusing to investors. Such items could have a material impact on GAAP measures of BD's financial performance. We also present our estimated adjusted revenue growth and organic revenue growth for our 2025 fiscal year after adjusting for the illustrative impact of foreign currency translation. BD believes that this adjustment allows investors to better evaluate BD's anticipated underlying earnings performance for our 2025 fiscal year in relation to our underlying 2024 fiscal year performance.

    Conference Call and Presentation Materials

    BD will host an audio webcast tomorrow for the public, investors, analysts, and news media to discuss its first quarter results. The audio webcast will be broadcast live on BD's website, www.bd.com/investors at 8 a.m. (ET) Thursday, February 6, 2025. Accompanying slides are available on BD's website, www.bd.com/investors. The conference call will be available for replay on BD's website, www.bd.com/investors. Alternatively, you can dial into the replay at 800-839-2486 (domestic) and 402-220-7223 (international) through the close of business on Thursday, February 13, 2025. A confirmation number is not needed to access the replay.

    Non-GAAP Financial Measures/Financial Tables

    This news release contains certain non-GAAP financial measures. These include revenue growth rates on a currency-neutral and organic basis and adjusted diluted earnings per share. These non-GAAP financial measures are not in accordance with generally accepted accounting principles in the United States. BD management believes that the use of non-GAAP measures to adjust for items that are considered by management to be outside of BD's underlying operational results or that affect period to period comparability helps investors to gain a better understanding of our performance year-over-year, to analyze underlying trends in our businesses, to analyze our operating results, and to understand future prospects. Management uses these non-GAAP financial measures to measure and forecast the company's performance, especially when comparing such results to previous periods or forecasts. We believe presenting such adjusted metrics provides investors with greater transparency to the information used by BD management for its operational decision-making and for comparison to other companies within the medical technology industry. Although BD's management believes non-GAAP results are useful in evaluating the performance of its business, its reliance on these measures is limited since items excluded from such measures may have a material impact on BD's net income, earnings per share or cash flows calculated in accordance with GAAP. Therefore, management typically uses non-GAAP results in conjunction with GAAP results to address these limitations. BD strongly encourages investors to review its consolidated financial statements and publicly filed reports in their entirety and cautions investors that the non-GAAP measures used by BD may differ from similar measures used by other companies, even when similar terms are used to identify such measures. Non-GAAP measures should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures.

    We present adjusted diluted earnings per share for the first quarter of fiscal year 2025, and the corresponding prior periods, after eliminating items we believe are not part of our ordinary operations and affect the comparability of the periods presented. Adjusted diluted earnings per share includes adjustments for the impact of purchase accounting adjustments, integration and restructuring costs, transaction costs, spin-off related costs, certain regulatory costs, certain product remediation costs, certain legal matters, certain investment gains and losses, certain asset impairment charges, and certain pension settlement costs. In particular, prior-year adjusted diluted earnings per share results exclude European regulatory initiative-related costs, which represent costs incurred to develop processes and systems to establish initial compliance with the European Union Medical Device Regulation and the European Union In Vitro Diagnostic Medical Device Regulation (collectively, the "New EU Medical Devices Regulations"), which represent a significant, unusual change to the existing regulatory framework. We consider the excluded European regulatory initiative-related costs to be duplicative of previously incurred costs and/or one-off costs related to establishing initial compliance with such regulatory regimes, and in each case are limited to a specific period of time. These expenses relate to establishing initial compliance with the New EU Medical Devices Regulations and include the cost of labor, other services and consulting (in particular, research and development and clinical trials) and supplies, travel and other miscellaneous costs. These costs were recorded in Cost of products sold and Research and development expense.

    We also present revenue growth rates for the first quarter of fiscal year 2025 over the corresponding prior periods on a currency-neutral basis after eliminating the effect of foreign currency translation, where applicable. We also show the growth in adjusted diluted earnings per share compared to the prior year periods after eliminating the impact of foreign currency translation to further enable investors to evaluate BD's underlying earnings performance compared to the prior periods. We calculate foreign currency-neutral percentages by converting our current-period local currency financial results using the prior period foreign currency exchange rates and comparing these adjusted amounts to our current-period results. As exchange rates are an important factor in understanding period-to-period comparisons, we believe the presentation of results on a foreign currency-neutral basis in addition to reported results helps improve investors' ability to understand our operating results and evaluate our performance in comparison to the prior periods.

    Reconciliations of these and other non-GAAP measures to the comparable GAAP measures are included in the attached financial tables. Within the attached financial tables presented, certain columns and rows may not add due to the use of rounded numbers. Percentages and earnings per share amounts presented are calculated from the underlying amounts.

    About BD

    BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/ and on X (formerly known as Twitter) @BDandCo.

    ***

    This press release and accompanying audio webcast on February 6, 2025 contain certain estimates and other forward-looking statements (as defined under Federal securities laws) regarding BD's future prospects and performance, including, but not limited to, statements relating to future revenues, margins, earnings per share, leverage targets and capital deployment. All such statements are based upon current expectations and assumptions of BD and involve a number of business risks and uncertainties. Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement. With respect to such forward-looking statements, a number of factors could cause actual results to vary materially. These factors include, but are not limited to, risks relating to macroeconomic conditions and their impact on our operations and healthcare spending generally, including any impact of disruptions in the global transportation networks or other aspects of our supply chain on our ability to source raw materials, components and energy sources needed to produce our products, labor constraints or disputes, inflationary pressures, currency rate fluctuations, and increased interest rates and borrowing costs; conditions in international markets, including geopolitical developments such as the evolving situations in Russia and Ukraine, the Middle East and Asia, which could adversely impact our operations; competitive factors including technological advances and new products or novel medical therapies introduced by competitors; product efficacy or safety concerns or non-compliance with applicable regulatory requirements (such as non-compliance of our products with registration requirements resulting from modifications to such products, or other factors, including with respect to BD Alaris™ pumps and related sets and BD Vacutainer™) resulting in product recalls, lost revenue or other actions being taken with respect to products in the field or the ability to continue selling new products to customers; changes to legislation or regulations impacting the U.S. or foreign healthcare systems, changes in medical practices or in patient preferences, potential cuts or freezes in governmental research or other healthcare spending, or governmental or private measures to contain healthcare costs, such as China's volume-based procurement tender process or changes in pricing and reimbursement policies, which could result in reduced demand for our products or downward pricing pressure; new or changing laws and regulations impacting our business (including the imposition of tariffs, such as those relating to China, Mexico, or other countries and regions in which we do business, sanctions, changes in tax laws, new environmental laws and regulations (such as those related to climate change or materials of concern), new cybersecurity, artificial intelligence or privacy laws, or changes in laws impacting international trade, including import and export licensing requirements, or anti-corruption and bribery, or changes in reporting requirements or enforcement practices with respect to such laws; the adverse impact on our business or products of past, current or future information and technology system disruptions, breaches or breakdowns, including through cyberattacks, ransom attacks or cyber-intrusion, and any investigations, legal proceedings, liability, expense or reputational damage arising in connection with any such events; increased labor costs and labor shortages or disputes; our suppliers' ability to provide products needed for our operations and BD's ability to maintain favorable supplier arrangements and relationships; increases in energy costs and their effect on, among other things, the cost of producing BD's products; adverse changes in regional, national or foreign economic conditions, including any impact on our ability to access credit markets and finance our operations; risks relating to our overall indebtedness; the possible impact of public health crises on our business and the global healthcare system, which could decrease demand for our products, disrupt our operations or the operations of our customers and companies within our supply chain, or increase transportation costs; interruptions in our manufacturing or sterilization processes or those of our third-party providers, including any restrictions placed on the use of ethylene oxide for sterilization; pricing and market pressures; difficulties inherent in product development, delays in product introductions and uncertainty of market acceptance of new products; the overall timing of the replacement or remediation of the BD Alaris™ Infusion System and return to market in the U.S., which may be impacted by, among other things, customer readiness, supply continuity and our continued engagement with the FDA; our ability to achieve our projected level or mix of product sales; our ability to successfully integrate any businesses we acquire; uncertainties of litigation, investigations, subpoenas, settlements, fines, penalties and/or other sanctions (as described in BD's filings with the Securities and Exchange Commission ("SEC")); the issuance of new or revised accounting standards; risks associated with the impact, timing or terms of the contemplated separation of BD's Biosciences and Diagnostic Solutions business; risks associated with the expected benefits and costs of the contemplated separation, including the risk that the expected benefits of the separation will not be realized within the expected time frame, in full or at all, and the risk that any conditions to the separation will not be satisfied and/or that the separation will not be completed within the anticipated time frame, on the anticipated terms or at all; the risk that any consents or approvals required in connection with the contemplated separation will not be received or obtained within the expected time frame, on the expected terms or at all; the risk that dis-synergy costs, costs of restructuring transactions and other costs incurred in connection with the contemplated separation will exceed BD's estimates; the impact of the contemplated separation on BD's businesses and the risk that the contemplated separation may be more difficult, time-consuming or costly than expected, including the impact on BD's resources, systems, procedures and controls, diversion of management's attention and the impact on relationships with customers, suppliers, employees and other business counterparties, as well as other factors discussed in BD's filings with the SEC. There can be no assurance that the contemplated separation will in fact be completed, in the manner described or at all. We do not intend to update any forward-looking statements to reflect events or circumstances after the date hereof except as required by applicable laws or regulations.

    Contacts:

    Investors: Adam Reiffe, Sr. Director, Investor Relations - 201-847-6927

    Media: Troy Kirkpatrick, VP, Public Relations - 858-617-2361

     

    BECTON DICKINSON AND COMPANY

    CONDENSED CONSOLIDATED INCOME STATEMENTS

    (Unaudited; Amounts in millions, except share and per share data)  







    Three Months Ended December 31,





    2024



    2023



    % Change

    REVENUES



    $

    5,168





    $

    4,706





    9.8

















    Cost of products sold



    2,933





    2,679





    9.5



    Selling and administrative expense



    1,318





    1,213





    8.7



    Research and development expense



    343





    290





    18.2



    Integration, restructuring and transaction expense



    92





    75





    23.9



    Other operating expense, net



    28





    11





    168.8



    TOTAL OPERATING COSTS AND EXPENSES



    4,715





    4,267





    10.5



    OPERATING INCOME



    453





    439





    3.2

















    Interest expense



    (155)





    (111)





    39.2



    Interest income



    23





    34





    (33.5)



    Other expense, net



    (16)





    (4)





    (279.8)



    INCOME BEFORE INCOME TAXES



    306





    359





    (14.7)



    Income tax provision



    3





    77





    (96.4)



    NET INCOME



    303





    281





    7.8

















    Basic Earnings per Share



    $

    1.05





    $

    0.97





    8.2



    Diluted Earnings per Share



    $

    1.04





    $

    0.96





    8.3

















    AVERAGE SHARES OUTSTANDING (in thousands)













    Basic



    289,505



    290,113





    Diluted



    290,389



    291,398









     

    BECTON DICKINSON AND COMPANY

    CONDENSED CONSOLIDATED BALANCE SHEETS

    (Amounts in millions)







    December 31, 2024



    September 30, 2024





    (Unaudited)





    ASSETS









    Cash and equivalents



    $

    711





    $

    1,717



    Restricted cash



    102





    139



    Short-term investments



    17





    445



    Trade receivables, net



    2,638





    3,033



    Inventories



    3,860





    3,843



    Prepaid expenses and other



    1,331





    1,292



    TOTAL CURRENT ASSETS



    8,659





    10,468



    Property, plant and equipment, net



    6,602





    6,821



    Goodwill and other intangibles, net



    36,817





    37,383



    Other assets



    2,586





    2,615



    TOTAL ASSETS



    $

    54,665





    $

    57,286



    LIABILITIES AND SHAREHOLDERS' EQUITY









    Current debt obligations



    $

    1,318





    $

    2,170



    Other current liabilities



    6,347





    6,786



    Long-term debt



    17,440





    17,940



    Long-term employee benefit obligations



    939





    942



    Deferred income taxes and other liabilities



    3,418





    3,558



    Shareholders' equity



    25,205





    25,890



    TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY



    $

    54,665





    $

    57,286



     

    BECTON DICKINSON AND COMPANY

    CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

    (Unaudited; Amounts in millions)







    Three Months Ended December 31,





    2024



    2023

    OPERATING ACTIVITIES









    Net income



    $

    303





    $

    281



    Depreciation and amortization



    607





    561



    Change in operating assets and liabilities and other, net



    (217)





    13



    NET CASH PROVIDED BY CONTINUING OPERATING ACTIVITIES



    693





    855



    INVESTING ACTIVITIES









    Capital expenditures



    (105)





    (116)



    Acquisitions, net of cash acquired



    (8)





    —



    Maturities and sales of investments



    411





    —



    Other, net



    (94)





    (116)



    NET CASH PROVIDED BY (USED FOR) INVESTING ACTIVITIES



    204





    (233)



    FINANCING ACTIVITIES









    Change in short-term debt



    75





    —



    Payments of debt



    (875)





    —



    Repurchases of common stock



    (750)





    (500)



    Dividends paid



    (302)





    (275)



    Other, net



    (76)





    (87)



    NET CASH USED FOR FINANCING ACTIVITIES



    (1,928)





    (862)



    Net cash used for operating activities of discontinued operations



    —





    (14)



    Effect of exchange rate changes on cash and equivalents and restricted cash



    (12)





    7



    NET DECREASE IN CASH AND EQUIVALENTS AND RESTRICTED CASH



    (1,043)





    (247)



    OPENING CASH AND EQUIVALENTS AND RESTRICTED CASH



    1,856





    1,481



    CLOSING CASH AND EQUIVALENTS AND RESTRICTED CASH



    $

    813





    $

    1,234



     

    BECTON DICKINSON AND COMPANY

    SUPPLEMENTAL REVENUE INFORMATION

    REVENUES BY BUSINESS SEGMENTS AND UNITS - UNITED STATES

    Three Months Ended December 31,

    (Unaudited; Amounts in millions)







    A



    B



    C=(A-B)/B





    2024



    2023



    % Change

    BD MEDICAL













    Medication Delivery Solutions



    $

    694





    $

    639





    8.6



    Medication Management Solutions



    659





    594





    11.0



    Pharmaceutical Systems



    104





    127





    (18.5)



    Advanced Patient Monitoring



    159





    —





    NM    

    TOTAL



    $

    1,615





    $

    1,360





    18.7

















    BD LIFE SCIENCES













    Specimen Management (1)



    $

    238





    $

    234





    2.0



    Diagnostic Solutions (1)



    212





    210





    1.0



    Biosciences



    153





    143





    6.6



    TOTAL



    $

    603





    $

    587





    2.8

















    BD INTERVENTIONAL













    Surgery



    $

    303





    $

    280





    8.0



    Peripheral Intervention



    253





    234





    7.8



    Urology and Critical Care



    306





    287





    6.6



    TOTAL



    $

    861





    $

    802





    7.4

















    TOTAL UNITED STATES



    $

    3,080





    $

    2,749





    12.0





    "NM" denotes that the percentage change is not meaningful.

    (1)

    During the first quarter of fiscal year 2025, Life Sciences split its former Integrated Diagnostic Solutions organizational unit into two units to better align BD resources with the distinct needs of each business.

     

    BECTON DICKINSON AND COMPANY

    SUPPLEMENTAL REVENUE INFORMATION

    REVENUES BY BUSINESS SEGMENTS AND UNITS - INTERNATIONAL

    Three Months Ended December 31, (continued)

    (Unaudited; Amounts in millions)



















    D=(A-B)/B



    E=(A-B-C)/B





    A



    B



    C



    % Change





    2024



    2023



    FX Impact



    Reported



    FXN

    BD MEDICAL





















    Medication Delivery Solutions



    $

    430





    $

    413





    $

    1





    4.3





    4.1



    Medication Management Solutions



    142





    153





    2





    (6.9)





    (8.2)



    Pharmaceutical Systems



    314





    304





    —





    3.2





    3.2



    Advanced Patient Monitoring



    113





    —





    1





    NM    



    NM    

    TOTAL



    $

    999





    $

    870





    $

    3





    14.9





    14.5

























    BD LIFE SCIENCES





















    Specimen Management (1)



    $

    223





    $

    213





    $

    —





    4.8





    4.7



    Diagnostic Solutions (1)



    262





    256





    1





    2.2





    1.9



    Biosciences



    208





    232





    1





    (10.1)





    (10.7)



    TOTAL



    $

    694





    $

    701





    $

    2





    (1.1)





    (1.4)

























    BD INTERVENTIONAL





















    Surgery



    $

    92





    $

    88





    $

    1





    4.1





    2.9



    Peripheral Intervention



    220





    220





    1





    0.2





    (0.4)



    Urology and Critical Care



    83





    78





    1





    6.8





    5.4



    TOTAL



    $

    396





    $

    386





    $

    4





    2.4





    1.5

























    TOTAL INTERNATIONAL



    $

    2,089





    $

    1,957





    $

    9





    6.7





    6.3





    "NM" denotes that the percentage change is not meaningful.

    (1)

    During the first quarter of fiscal year 2025, Life Sciences split its former Integrated Diagnostic Solutions organizational unit into two units to better align BD resources with the distinct needs of each business.

     

    BECTON DICKINSON AND COMPANY

    SUPPLEMENTAL REVENUE INFORMATION

    REVENUES BY BUSINESS SEGMENTS AND UNITS - TOTAL

    Three Months Ended December 31, (continued)

    (Unaudited; Amounts in millions)



















    D=(A-B)/B



    E=(A-B-C)/B





    A



    B



    C



    % Change





    2024



    2023



    FX Impact



    Reported



    FXN

    BD MEDICAL





















    Medication Delivery Solutions



    $

    1,124





    $

    1,052





    $

    1





    6.9





    6.8



    Medication Management Solutions



    801





    747





    2





    7.3





    7.1



    Pharmaceutical Systems



    418





    431





    —





    (3.2)





    (3.2)



    Advanced Patient Monitoring



    271





    —





    1





    NM    



    NM    

    TOTAL



    $

    2,615





    $

    2,230





    $

    3





    17.3





    17.1

























    BD LIFE SCIENCES





















    Specimen Management (1)



    $

    462





    $

    447





    $

    —





    3.3





    3.3



    Diagnostic Solutions (1)



    474





    467





    1





    1.7





    1.5



    Biosciences



    361





    375





    1





    (3.7)





    (4.1)



    TOTAL



    $

    1,297





    $

    1,288





    $

    2





    0.7





    0.5

























    BD INTERVENTIONAL





















    Surgery



    $

    395





    $

    369





    $

    1





    7.0





    6.8



    Peripheral Intervention



    473





    454





    1





    4.1





    3.8



    Urology and Critical Care



    389





    365





    1





    6.6





    6.3



    TOTAL



    $

    1,257





    $

    1,188





    $

    4





    5.8





    5.5

























    TOTAL REVENUES



    $

    5,168





    $

    4,706





    $

    9





    9.8





    9.6





    "NM" denotes that the percentage change is not meaningful.

    (1)

    During the first quarter of fiscal year 2025, Life Sciences split its former Integrated Diagnostic Solutions organizational unit into two units to better align BD resources with the distinct needs of each business.

     

    BECTON DICKINSON AND COMPANY

    SUPPLEMENTAL REVENUE INFORMATION

    RECONCILIATION OF REPORTED REVENUE CHANGE TO ORGANIC REVENUE CHANGE

    Three Months Ended December 31,

    (Unaudited; Amounts in millions)



















    D = (A-B)/B



    E=(A-B-C)/B





    A



    B



    C



    % Change





    2024



    2023



    FX Impact



    Reported



    FXN

    TOTAL REVENUES



    $

    5,168





    $

    4,706





    $

    9





    9.8





    9.6



    Less: Inorganic revenue adjustment (1)



    271





    —





    1





    NM    



    NM  

    Organic Revenue



    $

    4,897





    $

    4,706





    $

    8





    4.1





    3.9

























    BD MEDICAL REVENUES



    $

    2,615





    $

    2,230





    $

    3





    17.3





    17.1



    Less: Inorganic revenue adjustment (1)



    271





    —





    1





    NM    



    NM   

    BD Medical Organic Revenue



    $

    2,343





    $

    2,230





    $

    3





    5.1





    5.0





    "NM" denotes that the percentage change is not meaningful.

    (1)

    Inorganic revenue adjustment is defined as the amount of incremental revenue attributable to acquisitions and the revenue decline attributable to divestitures during the first 12 months post-acquisition/divestiture. Acquisitions include: Advanced Patient Monitoring in the Medical Segment.

     

    BECTON DICKINSON AND COMPANY









    SUPPLEMENTAL INFORMATION









    RECONCILIATION OF REPORTED DILUTED EPS TO ADJUSTED DILUTED EPS









    (Unaudited)







































    Three Months Ended December 31,



    2024



    2023



    Change



    Translational FX



    FXN

    Change



    Change %



    FXN

    Change %

    Reported Diluted Earnings per Share

    $

    1.04





    $

    0.96





    $

    0.08





    $

    0.01





    $

    0.07





    8.3 %



    7.3 %

    Purchase accounting adjustments ($570 million and $362 million pre-tax, respectively) (1)

    1.96





    1.24









    —















    Integration costs ($24 million and $5 million pre-tax, respectively) (2)

    0.08





    0.02









    —















    Restructuring costs ($66 million and $69 million pre-tax, respectively) (2)

    0.23





    0.24









    —















    Transaction Costs ($3 million pre-tax) (3)

    0.01





    —









    —















    Separation-related items ($2 million pre-tax, respectively) (4)

    —





    0.01









    —















    European regulatory initiative-related costs ($23 million pre-tax, respectively) (5)

    —





    0.08









    —















    Product, litigation, and other items ($102 million and $14 million pre-tax, respectively) (6)

    0.35





    0.05









    —















    Tax impact of specified items and other tax related (($71) million and $24 million, respectively)

    (0.24)





    0.08









    —















    Adjusted Diluted Earnings per Share

    $

    3.43





    $

    2.68





    $

    0.75





    $

    0.01





    $

    0.74





    28.0 %



    27.6 %





    (1)

    Includes amortization and other adjustments related to the purchase accounting for acquisitions.

    (2)

    Represents costs associated with integration and restructuring activities.

    (3)

    Represents transaction costs recorded to Integration, restructuring and transaction expense incurred in connection with the Advanced Patient Monitoring acquisition.

    (4)

    Represents costs recorded to Other operating expense, net incurred in connection with the separation of BD's former Diabetes Care business.

    (5)

    Represents costs incurred to develop processes and systems to establish initial compliance with the European Union Medical Device Regulation and the European Union In Vitro Diagnostic Medical Device Regulation, which represent a significant, unusual change to the existing regulatory framework. We consider these costs to be duplicative of previously incurred costs and/or one-off costs, which are limited to a specific period of time. These expenses, which are recorded in Cost of products sold and Research and development expense, include the cost of labor, other services and consulting (in particular, research and development and clinical trials) and supplies, travel and other miscellaneous costs.

    (6)

    Includes certain (income) expense items which are not part of ordinary operations and affect the comparability of the periods presented. Such items may include certain product remediation costs, certain legal matters, certain investment gains and losses, certain asset impairment charges, and certain pension settlement costs. The amount for the three months ended December 31, 2024 reflects a charge of $22 million to Cost of products sold to adjust the estimate of future product remediation costs, a charge of $30 million to Research and development expense related to a non-cash asset impairment charge in the Life Sciences segment, and charges of $29 million to Other operating expense, net, related to various legal matters.

     

    BECTON DICKINSON AND COMPANY

    SUPPLEMENTAL INFORMATION

    FY 2025 OUTLOOK RECONCILIATION















































    Full Year FY 2024



    Full Year FY 2025 Outlook





    ($ in millions)



    % Change



    Revenues

    BDX Reported Revenues



    $

    20,178











    Add: Revenue Adjustment Impact



    67











    Adjusted Revenues



    $

    20,245

























    FY 2025 Reported Revenue Growth







    +7.9% to +8.4%





    Revenue Adjustment Impact







    ~+35 basis points





    Illustrative Foreign Currency (FX) Impact







    (~125) basis points





    FY 2025 Revenue Growth (adjusted) (FXN)







    +8.8% to 9.3%





    FY 2025 Inorganic Impact to Revenue Growth







    ~+475 basis points





    FY 2025 Organic Revenue Growth (FXN)







    +4.0% to +4.5%



















    Total FY 2025 Revenues











    ~$21.7 to $21.9 billion



    Notes

    - Revenue Adjustment Impact reflects the recognition of accruals resulting from developments relating to the Italian government medical device pay back legislation, as well as another legal matter, and which substantially relate to years prior to fiscal year 2024.

    - Inorganic revenue adjustment is defined as the amount of incremental revenue attributable to acquisitions and the revenue decline attributable to divestitures during the first 12 months post-acquisition/divestiture.

     

    BECTON DICKINSON AND COMPANY

    SUPPLEMENTAL INFORMATION

    FY 2025 OUTLOOK RECONCILIATION CONTINUED











    Full Year FY 2025 Outlook





    Full Year FY 2024 from Continuing Operations



    Total Company

    Reported Diluted Earnings per Share



    $

    5.86











    Purchase accounting adjustments ($1.503 billion pre-tax) (1)



    5.16











    Integration costs ($23 million pre-tax) (2)



    0.08











    Restructuring costs ($387 million pre-tax) (2)



    1.33











    Transaction Costs ($48 million pre-tax) (3)



    0.17











    Financing Costs (($8) million pre-tax) (3)



    (0.03)











    Separation-related items ($13 million pre-tax) (4)



    0.05











    European regulatory initiative-related costs ($104 million pre-tax) (5)



    0.36











    Product, litigation, and other items ($346 million pre-tax) (6)



    1.19











    Tax impact of specified items and other tax related (($297) million)



    (1.02)











    Adjusted Diluted Earnings per Share



    $

    13.14





    $14.30 to $14.60

    Reported % Change







    +8.8% to +11.0%





    (1)

    Includes amortization and other adjustments related to the purchase accounting for acquisitions.

    (2)

    Represents costs associated with integration and restructuring activities.

    (3)

    Represents transaction costs and financing impacts associated with the Advanced Patient Monitoring acquisition. The transaction costs are recorded in Integration, restructuring and transaction expense and the financing impacts are recorded in Interest income and Interest expense.

    (4)

    Represents costs recorded to Other operating expense (income), net incurred in connection with the separation of BD's former Diabetes Care business.

    (5)

    Represents costs incurred to develop processes and systems to establish initial compliance with the European Union Medical Device Regulation and the European Union In Vitro Diagnostic Medical Device Regulation, which represent a significant, unusual change to the existing regulatory framework. We consider these costs to be duplicative of previously incurred costs and/or one-off costs, which are limited to a specific period of time. These expenses, which are recorded in Cost of products sold and Research and development expense, include the cost of labor, other services and consulting (in particular, research and development and clinical trials) and supplies, travel and other miscellaneous costs.

    (6)

    Includes certain (income) expense items which are not part of ordinary operations and affect the comparability of the periods presented. Such items may include certain product remediation costs, certain legal matters, certain investment gains and losses, certain asset impairment charges, and certain pension settlement costs. The amount in 2024 reflects the recognition of $67 million in accruals as an impact to Revenues resulting from recent developments relating to the Italian government medical device pay back legislation, as well as another legal matter, and which substantially relate to years prior to our current fiscal year, and charges of $38 million to Cost of products sold to record or adjust future costs for product remediation efforts. The amount in 2024 also reflects charges to Other operating expense (income), net related to legal matters, including a $175 million charge to accrue an estimated liability for the SEC investigation with respect to, among other things, certain reporting issues involving BD AlarisTM infusion pumps included in SEC disclosures prior to 2021.

     

    Cision View original content:https://www.prnewswire.com/news-releases/bd-reports-first-quarter-fiscal-2025-financial-results-302369318.html

    SOURCE BD (Becton, Dickinson and Company)

    Get the next $BDX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BDX

    DatePrice TargetRatingAnalyst
    5/2/2025$185.00Overweight → Neutral
    Piper Sandler
    5/2/2025$192.00Buy → Neutral
    Goldman
    5/2/2025Outperform → Mkt Perform
    Raymond James
    5/1/2025Overweight → Equal Weight
    Wells Fargo
    5/1/2025$190.00Buy → Neutral
    BofA Securities
    5/1/2025Outperform → Mkt Perform
    William Blair
    10/1/2024$255.00 → $275.00Neutral → Buy
    Citigroup
    5/30/2024$274.00Buy
    Goldman
    More analyst ratings

    $BDX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • BD Reports Second Quarter Fiscal 2025 Financial Results

      Revenue of $5.3 billion increased 4.5% as reported, 6.0% currency-neutral and 0.9% organicGAAP and adjusted diluted EPS of $1.07 and $3.35, respectivelyCompany updates full-year fiscal 2025 guidance and provides estimated tariff impactFRANKLIN LAKES, N.J., May 1, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced results for its fiscal 2025 second quarter, which ended March 31, 2025. "Amid a difficult operating environment impacting near-term organic revenue growth, our Q2 results reflect the strength of our business model and ability to exceed our earnings expectations through quality gross margin improvement," s

      5/1/25 6:30:00 AM ET
      $BDX
      Medical/Dental Instruments
      Health Care
    • BD to Present at Bank of America Securities Health Care Conference

      FRANKLIN LAKES, N.J., April 30, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced that it will present at the Bank of America Securities Health Care Conference on Tuesday, May 13, 2025 at 1:00 pm Eastern Time. The live webcast of BD's presentation can be accessed from the BD investor relations website, investors.bd.com. A replay of the event will be available on the same webpage following its conclusion. About BDBD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports th

      4/30/25 4:15:00 PM ET
      $BDX
      Medical/Dental Instruments
      Health Care
    • BD Board Declares Dividend

      FRANKLIN LAKES, N.J., April 29, 2025 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced it has declared a quarterly dividend of $1.04 per common share, payable on June 30, 2025 to holders of record on June 9, 2025. The indicated annual dividend rate is $4.16 per share. About BDBD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advanc

      4/29/25 4:20:00 PM ET
      $BDX
      Medical/Dental Instruments
      Health Care

    $BDX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Becton Dickinson downgraded by Piper Sandler with a new price target

      Piper Sandler downgraded Becton Dickinson from Overweight to Neutral and set a new price target of $185.00

      5/2/25 8:06:47 AM ET
      $BDX
      Medical/Dental Instruments
      Health Care
    • Becton Dickinson downgraded by Goldman with a new price target

      Goldman downgraded Becton Dickinson from Buy to Neutral and set a new price target of $192.00

      5/2/25 8:06:36 AM ET
      $BDX
      Medical/Dental Instruments
      Health Care
    • Becton Dickinson downgraded by Raymond James

      Raymond James downgraded Becton Dickinson from Outperform to Mkt Perform

      5/2/25 8:06:16 AM ET
      $BDX
      Medical/Dental Instruments
      Health Care

    $BDX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Jones Christopher Ian Montague

      4 - BECTON DICKINSON & CO (0000010795) (Issuer)

      5/7/25 7:22:33 PM ET
      $BDX
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Director Byington Carrie L

      4 - BECTON DICKINSON & CO (0000010795) (Issuer)

      5/7/25 7:20:56 PM ET
      $BDX
      Medical/Dental Instruments
      Health Care
    • EVP & President, Medical Garrison Michael David sold $94,497 worth of shares (479 units at $197.28), decreasing direct ownership by 9% to 4,887 units (SEC Form 4)

      4 - BECTON DICKINSON & CO (0000010795) (Issuer)

      4/10/25 1:56:11 PM ET
      $BDX
      Medical/Dental Instruments
      Health Care

    $BDX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Henderson Jeffrey William bought $350,430 worth of shares (1,500 units at $233.62), increasing direct ownership by 23% to 8,015 units (SEC Form 4)

      4 - BECTON DICKINSON & CO (0000010795) (Issuer)

      2/10/25 5:03:18 PM ET
      $BDX
      Medical/Dental Instruments
      Health Care

    $BDX
    Financials

    Live finance-specific insights

    See more
    • BD Reports Second Quarter Fiscal 2025 Financial Results

      Revenue of $5.3 billion increased 4.5% as reported, 6.0% currency-neutral and 0.9% organicGAAP and adjusted diluted EPS of $1.07 and $3.35, respectivelyCompany updates full-year fiscal 2025 guidance and provides estimated tariff impactFRANKLIN LAKES, N.J., May 1, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced results for its fiscal 2025 second quarter, which ended March 31, 2025. "Amid a difficult operating environment impacting near-term organic revenue growth, our Q2 results reflect the strength of our business model and ability to exceed our earnings expectations through quality gross margin improvement," s

      5/1/25 6:30:00 AM ET
      $BDX
      Medical/Dental Instruments
      Health Care
    • BD Board Declares Dividend

      FRANKLIN LAKES, N.J., April 29, 2025 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced it has declared a quarterly dividend of $1.04 per common share, payable on June 30, 2025 to holders of record on June 9, 2025. The indicated annual dividend rate is $4.16 per share. About BDBD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advanc

      4/29/25 4:20:00 PM ET
      $BDX
      Medical/Dental Instruments
      Health Care
    • BD Reports First Quarter Fiscal 2025 Financial Results

      Company Delivers Revenue, Margin and Earnings Ahead of its Expectations Revenue of $5.2 billion increased 9.8% as reported, 9.6% currency-neutral and 3.9% organicGAAP and adjusted diluted EPS of $1.04 and $3.43 grew 8.3% and 28.0%, respectivelyBD completes $750 million share repurchase to date in FY25Company increases FY25 adjusted diluted EPS guidance at the midpoint while absorbing translational currency1FRANKLIN LAKES, N.J., Feb. 5, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced results for its fiscal 2025 first quarter which ended December 31, 2024. "We delivered strong operational performance in Q1, with

      2/5/25 4:30:00 PM ET
      $BDX
      Medical/Dental Instruments
      Health Care

    $BDX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Becton Dickinson and Company (Amendment)

      SC 13G/A - BECTON DICKINSON & CO (0000010795) (Subject)

      2/16/24 4:29:42 PM ET
      $BDX
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Becton Dickinson and Company (Amendment)

      SC 13G/A - BECTON DICKINSON & CO (0000010795) (Subject)

      2/14/24 10:02:59 AM ET
      $BDX
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Becton Dickinson and Company (Amendment)

      SC 13G/A - BECTON DICKINSON & CO (0000010795) (Subject)

      2/13/24 5:00:53 PM ET
      $BDX
      Medical/Dental Instruments
      Health Care

    $BDX
    SEC Filings

    See more
    • Becton Dickinson and Company filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

      8-K - BECTON DICKINSON & CO (0000010795) (Filer)

      5/2/25 4:34:41 PM ET
      $BDX
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-Q filed by Becton Dickinson and Company

      10-Q - BECTON DICKINSON & CO (0000010795) (Filer)

      5/1/25 4:30:56 PM ET
      $BDX
      Medical/Dental Instruments
      Health Care
    • Becton Dickinson and Company filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - BECTON DICKINSON & CO (0000010795) (Filer)

      5/1/25 6:32:47 AM ET
      $BDX
      Medical/Dental Instruments
      Health Care

    $BDX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • November 23, 2021 - Coronavirus (COVID-19) Update: November 23, 2021

      For Immediate Release: November 23, 2021 The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic: On Nov. 22, the FDA authorized three over-the-counter (OTC) COVID-19 antigen diagnostic tests for people age 14 years or older with a self-collected nasal swab sample or people age 2 years or older when an adult collects the nasal swa

      11/23/21 3:16:12 PM ET
      $BDX
      Medical/Dental Instruments
      Health Care
    • July 23, 2021 - Coronavirus (COVID-19) Update: July 23, 2021

      For Immediate Release: July 23, 2021 The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic: The agency updated its FDA COVID-19 Response At-A-Glance Summary, which provides a quick look at facts, figures and highlights on the FDA's response efforts. On Thursday, July 22 the FDA issued an Emergency Use Authorization (EUA) to Bec

      7/23/21 4:06:11 PM ET
      $BDX
      Medical/Dental Instruments
      Health Care

    $BDX
    Leadership Updates

    Live Leadership Updates

    See more
    • BD Names Gregory J. Hayes to Board of Directors

      FRANKLIN LAKES, N.J., March 27, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced the appointment of Gregory J. Hayes to its board of directors, effective March 26, 2025. Hayes, 64, is currently the executive chairman of the board of directors of RTX Corporation, the world's largest aerospace and defense company. He brings more than 30 years of extensive executive experience, having held chief executive officer and senior leadership roles across finance, corporate strategy and business development f

      3/27/25 4:15:00 PM ET
      $BDX
      Medical/Dental Instruments
      Health Care
    • Maravai LifeSciences Appoints R. Andrew Eckert as Chairman of the Board of Directors

      SAN DIEGO, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. ("Maravai" or the "Company") (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, announced that Carl Hull will retire from his position as Executive Chairman of the Board and that the Board of Directors has unanimously elected R. Andrew Eckert to succeed him as Chairman of the Board, effective December 5, 2024. Carl Hull founded Maravai in 2014 and served as Chief Executive Officer, assuming the role of Executive Chairman in October 2022. "Leading Maravai has been the single most rewarding experience in my career. I am extremely proud of what we have

      12/5/24 4:05:00 PM ET
      $BDX
      $FTRE
      $MRVI
      Medical/Dental Instruments
      Health Care
      Medical Specialities
      Biotechnology: Pharmaceutical Preparations
    • Revelyst Announces Chief Supply Chain Officer

      Revelyst is thrilled to appoint longtime supply chain and business operations leader Joe Beck to the position of Chief Supply Chain Officer. Revelyst, a collective of world-class maker brands that design and manufacture performance gear and precision technologies and a segment of Vista Outdoor Inc. (NYSE:VSTO), today announced the appointment of Joe Beck as Chief Supply Chain Officer, effective April 22. In the third quarter, Revelyst launched GEAR Up, the company's plan to simplify its business model, deliver increased efficiency and profitability, and reinvest in its highest potential brands to accelerate growth and transformation. The appointment of a seasoned, transformational supply

      4/23/24 7:00:00 AM ET
      $BDX
      $EMBC
      $VSTO
      Medical/Dental Instruments
      Health Care
      Ordnance And Accessories
      Industrials